{"classes":[{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"17.0","upperLimit":"NA","value":"NA"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"42.8","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"Non-Hodgkin Lymphoma (NHL): Diffuse Large B-cell Lymphoma (DLBCL)"},{"categories":[{"measurements":[{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: Follicular Lymphoma Grade 3B"},{"categories":[{"measurements":[{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"5.3","upperLimit":"NA","value":"16.3"},{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"7.9","upperLimit":"NA","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NIH: High-Grade B-cell Lymphoma with DLBCL Histology"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"17.9","upperLimit":"NA","value":"NA"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"11.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"NIH: Primary Mediastinal (thymic) Large B-cell Lymphoma"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.9","upperLimit":"NA","value":"NA"},{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: T Cell/Histiocyte-Rich Large B-Cell Lymphoma"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"16.7","upperLimit":"NA","value":"NA"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"42.8","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Diffuse Large B-cell Lymphoma (DLBCL): DLBCL NOS de novo"},{"categories":[{"measurements":[{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.0","upperLimit":"NA","value":"28.2"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"14.2","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"DLBCL: DLBCL from Transformed Indolent NHL"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"18.2","upperLimit":"NA","value":"NA"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"15.8","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"DLBCL: Germinal Center B-cell like (GCB)"},{"categories":[{"measurements":[{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"9.7","upperLimit":"NA","value":"16.3"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"32.4","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"DLBCL: Activated B-cell-like, non-GCB"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"30.7","value":"16.3"},{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"7.9","upperLimit":"NA","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NHL: Double-hit lymphoma (DBL)/triple-hit lymphoma (THL)"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"27.5","upperLimit":"NA","value":"NA"},{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"NHL: Non-DHL/THL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from randomization to death due to any cause. Estimates of time to event are from Kaplan-Meier product-limit estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized participants per clinical, histological and molecular subgroups that are pre-specified for OS (subgroups are not mutually exclusive)","reportingStatus":"POSTED","timeFrame":"From randomization to time of death due to any cause (Up to 36 months)","title":"Overall Survival (OS) by Subgroups","type":"SECONDARY","unitOfMeasure":"Months"}